Myriad Genetics CSO Jerry Lanchbury retires; severance $782k plus equity acceleration

MYRIAD GENETICS INC

Jerry Lanchbury retired as Chief Scientific Officer effective Jan 14, 2022, will consult through Mar 31, 2022.
Lump sum severance of $782,276.93; weekly consulting fee of $500; additional $45,401.67 possible at end.
Unvested equity awards scheduled to vest within two years of transition are accelerated, with performance-based awards subject to conditions.
Non-compete and non-solicitation covenants apply for 12 months after the consulting period.
Eligible for 2021 annual bonus as determined by Compensation Committee.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Jerry Lanchbury

Chief Scientific Officer

MYGN · MYRIAD GENETICS INC

Effective: 2022-01-14
Filed: February 9, 2022, 6:59 PM ET

As previously disclosed, Dr. Lanchbury announced his retirement as Chief Scientific Officer of the Company, effective January 14, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Jerry Lanchbury retired as Chief Scientific Officer at MYRIAD GENETICS INC.

Action: retired
Role: Chief Scientific Officer

Exact text from the filing

As previously disclosed, Dr. Lanchbury announced his retirement as Chief Scientific Officer of the Company, effective January 14, 2022.

View on SEC.gov

MYRIAD GENETICS INC filing history →

Source: SEC EDGAR

accession 0000899923-22-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.